Tech Company Financing Transactions
Metagenomi Funding Round
On 11/16/2020, Metagenomi raised $65 million in Series A funding from Humboldt Fund, Leaps by Bayer and Agent Capital.
Transaction Overview
Company Name
Announced On
11/16/2020
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series A
Investors
Humboldt Fund (Lead Investor) (Sebastian Bernales)
Leaps by Bayer (Lead Investor) (Juergen Eckhardt)
Proceeds Purpose
Capital raised during this round will enable Metagenomi to accelerate the expansion of its gene editing systems for potential therapeutic use.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5980 Horton St. 600
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Founded in 2018 by lead metagenomics researchers at UC Berkeley, Brian C. Thomas and Jillian Banfield, Metagenomi is committed to changing the landscape of cell and gene therapies. By using metagenomics to unlock 4 billion years of microbial evolution, Metagenomi is rapidly identifying and characterizing novel nucleases with unique gene editing capabilities.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Thomas
Chief Operating Officer
Jian Irish
VP - Bus. Development
Jak Knowles
VP - R & D
Alan Brooks
Browse more venture capital transactions:
Prev: 11/16/2020: ALICE Technologies venture capital transaction
Next: 11/16/2020: Kira Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs